Spruce Biosciences, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Spruce Biosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-12-31 was $0.00.
- Spruce Biosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $0.00.
- Spruce Biosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was $0.00.
- Spruce Biosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-03-31 was $180.00K.
- Spruce Biosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $5.00K, a 97.22% decline from fiscal 2024.
- Spruce Biosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $180.00K, a 17900.00% increase from fiscal 2023.
- Spruce Biosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $1.00K, a 50.00% decline from fiscal 2022.
- Spruce Biosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $2.00K, a 99.39% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2025-12-31 | $5.00K 10-K · filed 2026-03-09 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $180.00K 10-K · filed 2026-03-09 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | |
| 2024-03-31 | $180.00K 10-Q · filed 2025-05-06 | |
| 2023-12-31 | $1.00K 10-K · filed 2025-04-15 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $2.00K 10-K · filed 2024-03-18 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $170.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $187.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $2.00K 10-Q · filed 2023-05-15 | $267.00K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $168.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $328.00K 10-K · filed 2023-03-16 |
| 2021-09-30 | $17.00K 10-Q · filed 2022-11-10 | $160.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $80.00K 10-Q · filed 2022-08-10 | $186.00K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $63.00K 10-Q · filed 2022-05-11 | $114.00K derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $51.00K 10-K · filed 2022-03-14 |
| 2020-09-30 | $43.00K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $8.00K 10-Q · filed 2020-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |